Quantity of eligible clients: CDEC talked over the uncertainty in the volume of people with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who're classified as having moderate or reasonable condition might have a severe bleedin